Study to Evaluate a Nutraceutical Supplement for Treatment of Hair Loss and Thinning in Females
NCT ID: NCT03052413
Last Updated: 2019-01-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
21 participants
INTERVENTIONAL
2016-12-31
2017-11-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nutraceutical Supplement With Vegan Botanicals in Females With Self-Perceived Thinning Hair
NCT05332743
Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Women With Thinning Hair
NCT03206567
Prospective Study of Nutraceutical Supplements to Support Hair Growth in Females
NCT06376409
Evaluation of an Oral Hair Supplement to Improve Hair Strength and Support Growth in Women and Men
NCT06362941
Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Peri-menopausal and Menopausal Women With Thinning Hair
NCT04048031
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active
Nutrafol
Eligible subjects will receive Nutrafol® to take daily for 180 days
Placebo
placebo
Eligible subjects will receive Placebo to take daily for 180 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nutrafol
Eligible subjects will receive Nutrafol® to take daily for 180 days
placebo
Eligible subjects will receive Placebo to take daily for 180 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Skin type I-IV
3. Have self-reported thinning or hair loss for more than 6 months prior to screening
4. Clinically confirmed to have hair loss or thinning by the investigator via physical exam, including subjects with female pattern hair loss with Savin Classification score of I2-II1 as determined by the investigator (through medical history, physical exam and /or strong family history of hair loss as defined by 2 or more relatives known to have a similar Savin pattern of loss without diagnosed disease)
5. In good general health, as determined by the Investigator
6. Willing and able to attend all study visits
7. Willing to maintain the same hair style as at the Screening Visit for the duration of the study. If coloring hair, willing to color it with the same frequency of usage as in the past, making sure not to color within 3 weeks of an in-office appointment.
8. Willing to use a mild non-medicated shampoo and conditioner for the duration of the study (medicated shampoo and conditioner refer to any prescription shampoo or conditioner as well as any over-the counter medicated shampoo or conditioner, such as those for treatment of dandruff or promoting hair growth)
9. Willing to have their hair clipped and scalp tattoo
10. Have a negative urine pregnancy test at screening and be using, and continue to use for the duration of the study, an effective contraception method (ie, abstinence, barrier control, intrauterine device \[IUD\], or hormonal \[estrogen/progestin\] contraceptives) for at least one menstrual cycle prior to study; if using IUD or hormonal contraceptives - then at least 2 years prior to screening, the initiation of which should not have been associated with initiation of hair loss/thinning.
11. Be willing and able to cooperate with the requirements of the study.
12. Voluntarily sign and date an informed consent agreement approved by the Institutional Review Board.
13. Be able to complete and understand the various rating instruments in English.
14. Sponsor approved global image assessment of degree of thinning / hair loss
Exclusion Criteria
2. Scalp hair loss on the treatment area, due to disease, injury, or medical therapy
3. Subjects who are pregnant, planning to become pregnant or breastfeeding. A urine pregnancy test will be done to rule out pregnancy, or Subjects of childbearing potential who are not using an approved method of birth control (oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide or abstinence). Females of non-childbearing potential are defined as postmenopausal (absence of menstrual bleeding for one year), hysterectomy or bilateral oophorectomy.
4. Current skin disease (e.g., psoriasis, atopic dermatitis, skin cancer, eczema, sun damage, seborrheic dermatitis), cuts and or abrasions on the scalp or condition (e.g., sunburn, tattoos) on the treatment area that, in the opinion of the Investigator, might put the subject at risk or interfere with the study conduct or evaluations.
5. History of surgical correction of hair loss on the scalp/ Hair transplants.
6. Use of any products or devices purported to promote scalp hair growth (e.g., finasteride or minoxidil) within the 30 days prior to the Baseline Visit.
7. Use of anti-androgenic therapies (e.g., spironolactone, flutamide, cyproterone acetate, cimetidine) within 30 days prior to the Baseline Visit.
8. No history of burning, flaking, itching, and stinging of the scalp.
9. History of malignancy (except scc and bcc skin cancers) or undergoing chemotherapy or radiation treatments.
10. A known history of autoimmune thyroid disease, any other thyroid disorder/abnormality or other autoimmune disorders that in the opinion of the investigator may interfere with the study treatment.
11. A known history of depression or bi-polar disease or any other condition that may impact the subject's participation.
12. Subjects taking vitamin E supplements can participate, provided medication is interrupted 14 days before baseline visit.
13. Recent utilization of low level lasers.
14. Has any condition that the treating investigator or PI thinks may put the Subject at risk or interfere with their participation in the study.
15. Is involved in any injury litigation claims
16. Known history or recent bloodwork indicating iron deficiency, bleeding disorders or platelet dysfunction syndrome as well as subjects receiving anticoagulant therapy or smokers with usage \>20 cigarettes/day.
17. Use of any medications that are known to potentially cause hair loss or affect hair growth, as determined by PI.
21 Years
55 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sadick Research Group
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
New Jersey Plastic Surgery
Montclair, New Jersey, United States
Sadick Research Group
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SRG-Nutra-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.